Background: Reports suggest a relationship between circulating sex hormone levels and breast cancer risk, but genetic association studies have been inconclusive. We investigated the association between levels of sex hormones and single nucleotide polymorphisms (SNPs) in genes coding for the enzymes that regulate them. Methods: We assayed circulating levels of estradiol, testosterone, estrone, androstenedione, 17␣-hydroxyprogesterone, and sex hormone-binding globulin (SHBG) in 1975 normal postmenopausal women. Fifteen SNPs in the CYP17, CYP19, EDH17B2, SHBG, COMT, and CYP1B1 genes were genotyped in these postmenopausal women and in a breast cancer case-control study. Associations of genotypes with breast cancer risk were evaluated in the case-control study and with hormone levels in the postmenopausal women using multiple linear regression with assay batch, body mass index, parity, peri-or postmenopausal status, and age band as covariates. Results: CYP19 SNPs (rs10046 and [TCT]؉/؊) were associated with differences in estradiol level (P ‫؍‬ .0006 and P ‫؍‬ .0003, respectively) and the estradiol:testosterone ratio (P ‫؍‬ .000001 and P ‫؍‬ .002). SNP rs10046 explained 1.6% of the variance (r 2 ) in the estradiol:testosterone ratio. SHBG SNPs (5 untranslated region [5UTR] g-a and D356N) were associated with both SHBG levels (P<10 ؊6 and P ‫؍‬ .005) and the estradiol:SHBG ratio (P ‫؍‬ .000008 and P ‫؍‬ .01). These SNPs explained 2.4% and 0.6% of the variance in SHBG levels, respectively. SNPs in the other genes were not associated with differences in any hormone levels, and none were statistically significantly associated with breast cancer risk. 
Several lines of evidence suggest that women with a higher exposure to sex hormones, particularly estrogens, have a higher risk of developing breast cancer than women with lower exposure to sex hormones. Epidemiologic studies have indicated that breast cancer risk is higher in women with early menarche and late menopause, who have longer exposure to sex hormones (1) . Moreover, long-term use of the antiestrogen tamoxifen reduces the incidence of breast cancer, and adjuvant treatment with the aromatase inhibitor anastrozole, which reduces estrogen synthesis, reduces the incidence of contralateral breast cancer by more than 80% (2) . A recent overview analysis of nine prospective studies (3) found that circulating levels of several steroid hormones, including estrogens, androgens, and their precursors, are directly related to risk of breast cancer in postmenopausal women. Specifically, women with circulating estradiol levels in the highest quintile were estimated to have twice the risk of breast cancer of women with levels in the lowest quintile. Based on these data, the authors estimated that a doubling of estradiol levels would confer a 1.3-fold increased risk of breast cancer. An increased risk of breast cancer was also associated with increased circulating levels of the precursors and metabolites of estradiol:estrone, estrone sulfate, testosterone, androstenedione, and dehydroepiandrosterone sulfate. In addition, women with higher circulating levels of sex hormone-binding globulin (SHBG), a protein that binds to and restricts the biologic activity of estradiol and testosterone, had lower risk. Postmenopausal estradiol levels correlate with weight, but no other strong estradiol controlling factors have been identified. A reasonable hypothesis is that levels of estradiol and related hormones are largely under genetic control. If so, polymorphisms associated with estradiol levels would be expected, in turn, to be related to breast cancer risk.
In postmenopausal women, ovarian estrogen synthesis is negligible and estrogens are synthesized in peripheral tissues, such as subcutaneous fat (4) . The final stage of estrogen synthesis is catalyzed by the aromatase enzyme (encoded by the CYP19 gene), which converts the androgens androstenedione and testosterone to the estrogens estradiol and estrone, respectively ( Fig. 1) . Estrogen synthesis is therefore limited by circulating levels of androstenedione and testosterone, which are synthesized from 17-hydroxypregnenolone and 17-hydroxyprogesterone. 17-hydroxypregnenolone is quantitatively more important in the adrenal synthesis of androgens that circulate predominately in postmenopausal women than 17-hydroxyprogesterone (Fig. 1) . These reactions are catalyzed by 17␣-hydroxylase/17,20-lyase (encoded by the CYP17 gene). The interconversions of the less biologically active hormones androstenedione and estrone to their more active analogs testosterone and estradiol, respectively, are catalyzed by 17␤-hydroxysteroid dehydrogenase type 2 (encoded by EDH17B2), which is thus also a key candidate enzyme for controlling estradiol levels.
Circulating sex hormone levels are regulated after synthesis by SHBG. Circulating estradiol and testosterone bind to SHBG, which restricts the passage of these hormones across the cell membrane (5) . Active estradiol is taken out of the circulation by a number of metabolic enzymes. The phase I enzyme CYP1B1 has been considered particularly important in the context of breast cancer because it converts estradiol to 4-hydroxyestradiol, which has been found to be a carcinogen in a number of model systems (6) . One of the major pathways that protects against this potentially harmful metabolite involves catechol-O-methyltransferase (encoded by COMT), which further converts 4-hydroxyestradiol to 4-methoxyestradiol (7) .
To establish whether genetic variants in CYP17, CYP19, EDH17B2, SHBG, COMT, or CYP1B1 genes are associated with sex hormone levels, we determined the circulating levels of six hormones in 1975 normal postmenopausal women not taking hormone replacement therapy (HRT) and tested their association with 15 single nucleotide polymorphisms (SNPs) in these genes (Figs. 1 and 2). We further investigated the association of the same SNPs with risk of breast cancer in a case-control study of 1558 -6258 women.
SUBJECTS AND METHODS

Normal Postmenopausal Women
From the 25 000 participants in the European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) cohort study (8) , we selected, at random, 2115 women from a subset of the participants older than 55 years who had not menstruated for 1
Fig. 2.
Haplotype arrangements in the genes with multiple SNPs. The most common haplotypes for each gene are shown first. Haplotype frequencies, calculated by using the estimation-maximization algorithm on the data from this study, are given as percentages. Base changes are marked with boxes, and amino acid chances are shown as one-letter codes. Linkage disequilibrium (DЈ) values between SNP pairs are shown between arrowheads (Ͻ Ͼ). Where it has been possible to infer the order of mutational events, these are represented by arrows. year or more and who had not taken hormone replacement therapy for at least 3 months prior to sampling. Plasma, serum, and whole blood samples were previously obtained from postmenopausal women participating in the EPIC-Norfolk cohort study. The plasma and sera were stored at Ϫ70°C until analysis. Whole blood was collected and stored at Ϫ30°C prior to DNA extraction. Anthropometric measurements and information about dietary habits have also been collected from this cohort. Ethical approval was obtained from the Norwich Local Research Ethics Committee, LREC 98CN01. All study participants provided written informed consent.
Breast Cancer Case Patients and Control Subjects
Patients were drawn from the Anglian Breast Cancer Study (9) . The case collection is ongoing, resulting in a change in sample size over time. A minimum of 812 to a maximum of 2850 patients, younger than 70 years, had been recruited at the time of analysis. Control subjects, matched for age, ethnicity, and residence in the East Anglian region of the U.K. were recruited through the EPIC study (8) . Characteristics of the case patients and control subjects are shown in 
Sex Hormone Analysis in Normal Postmenopausal Women
For the first 151 patients, sex hormone measurements were made from stored serum samples. After conducting comparative studies, which established that there were only minor differences between values obtained from plasma or serum from the same individual, the remaining measurements were made on plasma samples.
Sex hormone analyses were carried out sequentially (in this order: estradiol, testosterone, SHBG, 17␣-hydroxyprogesterone, androstenedione, and estrone) on the available plasma or serum from each subject. More than 94% of the subjects had sufficient plasma or serum to complete the estradiol, testosterone, SHBG, and 17␣-hydroxyprogesterone measurements; thereafter, 71% of the subjects had sufficient plasma or serum for androstenedione measurements; in only 59% of subjects was there sufficient plasma or serum for estrone measurements.
Estradiol was measured from plasma or serum samples by radioimmunoassay after ether extraction (10) . The within-and between-batch coefficients of variation were 8.6% and 13%, respectively, at a concentration of 18 pmol/L, and the sensitivity limit was 3.0 pmol/L. Testosterone was measured by using a solid-phase radioimmunoassay kit (Diagnostic Products, Gwynedd, U.K.). Within-and between-batch coefficients of variation were 6.1% and 10%, respectively, at a concentration of 3.1 nmol/L, and the sensitivity limit was 0.14 nmol/L. SHBG was measured by using a liquid-phase immunoradiometric kit (Orion Diagnostica, Espoo, Finland). Within-and between-batch coefficients of variation were 2.1% and 7.4%, respectively, at a concentration of 11 nmol/L, and the sensitivity limit was 0.5 nmol/L. Androstenedione, 17␣-hydroxyprogesterone, and estrone were measured as described below by using Diagnostic Systems Laboratories detection kits (Oxford, U.K.) with an antibody dilution (1:1) modification for 17␣-hydroxyprogesterone. Androstenedione was estimated using solid-phase radioimmunoassay. Within-and between-batch coefficients of variation were 5.6% and 11%, respectively, at a concentration of 3.5 nmol/L, and the sensitivity was 0.1 nmol/L. 17␣-hydroxyprogesterone levels were measured by radioimmunoassay. Withinand between-batch coefficients of variation were 4.2% and 6.2%, respectively, at a concentration of 1.5 nmol/L, and the detection limit was 0.06 nmol/L. Estrone was measured by radioimmunoassay after extraction with ether and liquid column chromatography on a Lipidex 5000 (PerkinElmer, Boston, MA) with elution using chloroform : hexane : methanol (50 : 50 : 1). Within-and between-batch coefficients of variation were 14% and 22% at 55 pmol/L, and the sensitivity limit was 15 pmol/L.
Genotyping
DNA for genotyping was extracted from the whole blood samples of all subjects (normal postmenopausal women, breast cancer case patients, and control subjects) by Whatman Biosciences (Ely, U.K.). A total of 15 SNPs were analyzed (Fig. 3 ). All genotyping was carried out by using end-point Taqman assays (Applied Biosystems, Warrington, U.K.) in 96-or 384-well arrays that included blank wells as negative controls, according to the manufacturer's instructions. Primer and probe sequences and assay temperatures are shown in Fig. 3 . Assays were run on MJ Tetrad thermal cyclers (Genetics Research Instrumentation, Braintree, U.K.); genotypes were subsequently read on a 7700 or 7900 Sequence Detector (Applied Biosystems), according to the manufacturer's instructions. SNP assays were validated in the case-control studies, in which 2%-10% of the DNA samples were duplicated in the arrays. Greater than 99% concordance between duplicated samples was required for assays to be accepted for analysis. As a further quality control step, deviation of the genotype distributions from those expected Five counties in East Anglia Norfolk, East Anglia *Patients diagnosed from 1991-1996 who were younger than 56 years and consented to blood collection in 1996 and patients diagnosed from 1996 onward who were younger than 65 years and consented to blood collection within 1 year of diagnosis were eligible.
†This is an ongoing study. under Hardy-Weinberg equilibrium were also tested, and the P values are presented in Supplemental Table A1 (available at http://jncicancerspectrum.oupjournals.org/jnci/content/vol96/ issue12/). No statistically significant deviations were observed. Genotypes were obtained for more than 95% of all subjects for all assays, except in the normal postmenopausal women, in which genotypes at CYP19 IVS4 [TCT]ϩ/Ϫ and EDH17B2 Ser313Gly were obtained for 54% and 81% of subjects, respectively. The lower proportions for the last two assays were the result of there being insufficient reagents to complete the study rather than of any systematic technical failure.
Statistical Methods
For the normal postmenopausal women, multiple linear regression was used to evaluate the effects of each polymorphism on sex hormone levels. Regression analyses were performed using Stata7 (Stata Corporation, College Station, TX). Sex hormone levels were log-transformed prior to comparison with genotypes to achieve approximately normal distributions. Analyses were adjusted for the following covariates, which are known to be or are potentially associated with sex hormone levels: body mass index (defined as weight [kg] divided by the square of height [m 2 ]); number of live births (0, 1, 2, 3, or Ն4); menopausal status (1 year from last period, 2-5 years from last period, Ͼ5 years from last period); and age, in years, when blood was taken (55-59, 60 -64, 65-69, 70 -74, 75-79, Ն80). In 22 of the 2115 samples assayed, sex hormone levels were inconsistent with postmenopausal status (17 had estradiol levels greater than 150 pmol/L, five had testosterone levels greater than 3.5 nmol/L), and these samples were excluded; an additional 118 subjects were excluded because of a self-report of premenopausal status or HRT use that conflicted with the report provided at the time of blood sampling. The analyses are therefore based on a total of 1975 women.
We computed adjusted geometric means for each genotype by running the regression analyses without an overall mean parameter. A two-degree-of-freedom likelihood ratio test for homogeneity of the effect of each SNP was performed. We also performed a one-degree-of-freedom test for trend over the ordered allele categories by fitting a model in which genotype was coded according to the number of rare alleles. The percentage of the phenotypic variance explained by each genotype was estimated by subtracting the r 2 value for a model that included the parameters for each SNP from the r 2 for a model that excluded the SNP. Haplotype frequencies were estimated using the estimation-maximization algorithm implemented in the estimation-maximization program (11) .
In the breast cancer case-control studies, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression. All statistical tests were two-sided.
RESULTS
SNPs and Circulating Sex Hormone Levels
We began by analyzing the association of 15 SNPs in the CYP17, CYP19, EDH17B2, SHBG, CYP1B1, and COMT genes with circulating hormone levels in the normal postmenopausal women. The adjusted geometric means for each hormone level, by SNP genotype, together with the significance levels and the percentage of the total variance explained (r 2 ) by each SNP, are shown in Supplemental Table  A2 (available at http://jncicancerspectrum.oupjournals.org/ jnci/content/vol96/issue12/).
We found no statistically significant associations between levels of any of the hormones and SNPs in the CYP17, EDH17B2, CYP1B1, and COMT genes. Each of these variants explained less than 0.6% of the trait variance.
Statistically significant associations with hormone levels were found for two common bi-allelic polymorphisms in the CYP19 gene: a 3Ј untranslated region (3ЈUTR) t-c change (rs10046) and the silent [TCT]ϩ/Ϫ in IVS4. The 3ЈUTR t-c SNP was associated with differences in estradiol levels (means: tt, 17.07 pmol/L; tc, 15.70 pmol/L; cc, 14.99 pmol/L; P ϭ .0006; Table 2 ). Reduced estradiol levels were associated with the presence of the c allele, and this SNP accounted for 0.8% of the total variance in estradiol. This SNP was also associated with differences in estrone levels (P ϭ .004, r 2 ϭ .9%), in the estradiol: testosterone ratio (P ϭ .000001, r 2 ϭ 1.6%), in the estrone: androstenedione ratio (P ϭ .002, r 2 ϭ 1.2%), and in the estradiol:SHBG ratio (P ϭ .02, r 2 ϭ .4%), but not with absolute SHBG levels. Comparison of statistical models indicated that the effect of the 3ЈUTR SNP is consistent with an additive (or co-dominant) mode of action, with the c allele being associated with reduced estradiol and estrone levels and with reduced estradiol:testosterone, estrone:androstenedione, and estradiol: SHBG ratios. When compared with the most general model for estradiol, an additive model was an adequate fit (P ϭ .8), whereas the recessive (P ϭ .02) and dominant (P ϭ .006) models fit poorly. Table 2 ), with reduced estrone levels (P ϭ .002, r 2 ϭ 2.7%), and with reduced ratios of estradiol:testosterone (P ϭ .002, r 2 ϭ 1.4%), estrone:androstenedione (P ϭ .01, r 2 ϭ 1.7%), and estradiol: SHBG (P ϭ .02, r 2 ϭ .7%). Again, the effect was most consistent with an additive genetic model. Two SNPs in the SHBG gene-a g-a substitution in the 5ЈUTR and a D356N amino acid change encoded by another g-a substitution (rs6259) in exon 8 (Table 3 )-also show statistically significant associations with hormone levels. The 5ЈUTR a allele was associated with raised SHBG levels (means: gg, 39.26 nmol/L; ga, 44.05 nmol/L; aa, 49.76 nmol/L; PϽ10 Ϫ6 , r 2 ϭ 2.4%) and with a reduced estradiol:SHBG ratio (means: gg, 0.41; ga, 0.36; aa, 0.31; P ϭ .000008, r 2 ϭ 1.1%). The action of this SNP was most consistent with an additive effect of the a allele (in comparison with the general model; P ϭ .07 for the additive model; P ϭ .003 for the dominant model; PϽ10
Ϫ4 for a recessive model). The N356 substitution is also associated with raised SHBG levels (means: DD, 41.42 nmol/L; DN, 43.64 nmol/L; NN, 54.90 nmol/L; P ϭ .005, r 2 ϭ.6%) and a reduced estradiol:SHBG ratio (means: DD, 0.38; DN, 0.36; NN, 0.25; P ϭ .01, r 2 ϭ .4%). In contrast to the 5ЈUTR SNP, the effect of the N substitution is most consistent with a recessive effect (P ϭ .09 versus P ϭ .04 for an additive model and P ϭ .01 for a dominant model). Figure 2 illustrates the common haplotypes for each of the genes, based on the SNPs we assayed, with haplotype frequen- cies as estimated by the estimation-maximization algorithm. For every gene, we found that all SNPs were in strong linkage disequilibrium, and in each case, there were just three common haplotypes (the frequencies of all other haplotypes combined were less than 2% for all genes). For CYP17, CYP1B1, and COMT, comprehensive SNP searches of the coding regions, and 5Ј and 3ЈUTRs have been completed (12, 13) ; the common SNPs identified by these searches generate the same three common haplotypes, which are tagged by the SNPs used in this study. The two SNPs in CYP19 that we studied distinguish three common haplotypes, which are derived from one another by single mutational events (Fig. 2) . The rarer IVS4 [TCT]Ϫ allele appears to have arisen on a haplotype that already carried the relatively more common 3ЈUTR c allele. A fourth haplotype (not shown), which has probably arisen by recombination, has a frequency of only 2%. These haplotypes give rise to eight combined genotypes (Fig. 4, A) . Homozygotes for the 3ЈUTR c allele (regardless of IVS4 [TCT] genotype) have reduced mean estradiol:testosterone ratios (Fig. 4,  A) as well as reduced estrone, estradiol, and estrone:androstenedione and estradiol:SHBG ratios (data not shown) compared with homozygotes for the t allele. Model fitting suggests that the primary association is with the 3ЈUTR t-c SNP and that the effect of the IVS4 [TCT]ϩ/Ϫ may be explained by its linkage disequilibrium with the 3ЈUTR SNP-after adjusting for the effect of 3ЈUTR t-c, there was no significant effect of IVS4 [TCT]ϩ/Ϫ, whereas a model without 3ЈUTR t-c fitted poorly (P ϭ .02 compared with the full model).
Haplotypes and Combined Genotypes
The rare a and N alleles of the two SHBG SNPs appear to have arisen by separate mutational events from the common ancestral haplotype, which carried g and D alleles at the two positions (Fig. 2) . Multiple regression analysis suggested that the two SNPs are independently associated with SHBG level (PϽ10 Ϫ4 for the effects of either D356N or 5ЈUTR g-a, after adjusting for the effect of the other SNP) (Fig. 4, B) .
SNPs and Breast Cancer Risk
All 15 SNPs were also investigated in the East Anglian breast cancer case-control study and the detailed results are shown in Supplementary Table A1 (available at http://jncicancerspectrum. oupjournals.org/jnci/content/vol96/issue12/). Odds ratios are illustrated in Fig. 5 . No statistically significant associations were observed between any SNP and differences in susceptibility to breast cancer. The maximum point estimate was for SHBG D356N (OR for NN versus DD ϭ 1.53, 95% CI ϭ 0.90 to 2.59; P ϭ .2).
DISCUSSION
We observed statistically significant associations between SNPs in two genes, CYP19 and SHBG, and differential levels of specific hormones relevant to the known functions of the two gene products. CYP19 encodes the aromatase enzyme, which catalyzes the conversions of testosterone to estradiol and androstenedione to estrone-the final stage of estrogen production. Consistent with this role, we observed that the 3ЈUTR c allele of CYP19 was associated with statistically significantly reduced mean levels of both estradiol and estrone and reduced estradiol: testosterone and estrone:androstenedione ratios. However, the proportion of total variance explained by this genetic variant was small-the largest r 2 for this SNP was 1.6% (for the estradiol: testosterone ratio), and the same SNP accounted for only 0.8% of the variance in circulating estradiol levels. By comparison, in the normal postmenopausal women, 9.9% of the variance in circulating estradiol levels is explained by differences in body mass index (Luben RN: personal communication).
Our data indicate that the CYP19 3ЈUTR t-c change was more strongly associated with estradiol levels than the IVS4 [TCT]ϩ/Ϫ SNP. This result is consistent with the results of Kristensen et al. (14) , who have reported that the c allele is associated with lower levels of CYP19 mRNA in tumors. Although it remains possible that the association with estradiol levels may be due to another noncoding region polymorphism that is in linkage disequilibrium with the 3ЈUTR change, a more probable explanation is that the c allele generates less aromatase enzyme than the t allele and hence confers reduced overall enzyme activity.
The haplotype block structure and tagging SNPs of the CYP19 gene were recently published (15) . The entire coding region of CYP19 lies within a single block (although its numerous promoters fall into other blocks) that has just four common haplotypes in the U.S. Caucasian population. The two CYP19 SNPs examined here tag three of these four haplotypes. The 3ЈUTR t allele uniquely tags the most common haplotype, which we found to be associated with the highest estradiol levels. It remains to be seen whether all three haplotypes carrying the 3ЈUTR c allele, or just a subset of them, are associated with reduced estradiol levels. If all three haplotypes are found to be associated with similarly reduced estradiol levels, this would provide further evidence that the 3ЈUTR t-c change directly affects the activity of the aromatase enzyme.
Both SHBG SNPs that we examined were associated with differences in circulating SHBG levels and estradiol:SHBG ratios, but not total estradiol levels. Again, the proportions of the variance explained, although highly statistically significant, were small. The 5ЈUTR g-a SNP, which had the larger effect of the two SNPs, accounted for 2.4% of the variance in SHBG levels and 1.1% of the variance in the estradiol:SHBG ratio. The effects of these two SNPs appear to be independent, because their rare alleles occur on different haplotypes and have different modes of action (one dominant, one recessive). The N residue at codon 356 is believed to be the anchor site for an additonal carbohydrate group, which reduces the rate of clearance of SHBG from the circulation; the D allele cannot link to the carbohydrate group (16) . The 5ЈUTR change is more likely to affect the rate of production of SHBG than the rate of clearance, but again, it may be in linkage disequilibrium with another, functional change.
The high degrees of statistical significance obtained for these SNPs, despite the small r 2 values, serve to demonstrate the statistical power of this type of study, which is based on quantitative phenotypes close to the mode of action of the gene. These results also show that SNPs in the other genes we have studied (CYP17, EDH17B2, COMT, and CYP1B1) have little if any effect on the hormone variables we have measured. In the only similar study we know of, Haiman et al. (17) suggested an association of the CYP17 t-34c SNP with circulating hormone levels in a group of 297 postmenopausal women. The cc homozygotes had elevated (by 9%-17%) levels of estrone, estradiol, testosterone, and androstenedione compared with the tt homozygotes, and the difference in estrone levels was statistically significant (PϽ.01). It is possible that we have not assayed the functionally significant SNPs in these genes. However, the complete coding regions of CYP17, COMT, and CYP1B1 have been examined for variants (12, 13) and, although there are multiple SNPs in each gene, the SNPs in the coding sequence generate only three common haplotypes. Although we cannot exclude the possibility that other haplotypes tagged by noncoding SNPs exist, it seems likely that any common coding variant could explain only a small proportion of the total variance in estradiol levels. In the case of EDH17B2, which has a highly conserved pseudogene, it was possible to assay only one SNP: S313G. Again, the entire coding sequence of this gene has been examined for variants (18) , and this was the only common polymorphic amino acid substitution found. Because we were not able to use the haplotype tag approach on this gene, it is possible that there are other variants that substantially affect levels or function of this enzyme, particularly if they were not in strong linkage disequilibrium with the S313G substitution.
Our findings, coupled with the established associations between estradiol and SHBG levels and breast cancer risk, suggest that the polymorphisms in CYP19 and SHBG genes should be associated with the risk of breast cancer (and potentially other hormone-related diseases, such as osteoporosis). However, despite numerous studies, no clear associations of these genes with disease risk have emerged. Two studies have reported that the bi-allelic CYP19 [TCT]ϩ/Ϫ polymorphism is not associated with breast cancer risk (19, 20) , and we have obtained odds ratios very close to unity in our set of 2526 cases and 2594 controls ( Fig. 5 ; Supplementary Table A1 available at http://jncicancer spectrum.oupjournals.org/jnci/content/vol96/issue12/). For the CYP19 3ЈUTR c-t SNP, which is more strongly associated with hormone levels, Kristensen et al. (14) did report a significant association between the t allele and breast cancer risk (OR for tt/cc ϭ 2.00, 95% CI ϭ 1.28 to 3.11), but Haiman et al. (21) found no association (OR for tt/cc ϭ 0.87, 95% CI ϭ 0.67 to 1.27). Here we also failed to find a significant association, based on 2635 cases and 3630 controls (OR for tt/cc ϭ 1.07, 95% CI ϭ 0.93 to 1.23; P genotype distribution ϭ .6 for CYP19 3ЈUTR c-t). The two SNPs that we found to be independently associated with raised SHBG levels might be expected to be associated with a reduced risk of breast cancer by reducing circulating active estradiol. However, we found no statistically significant change in risk for the SHBG SNPs 5ЈUTR a-g (OR for aa/gg ϭ 1.02, 95% CI ϭ 0.75 to 1.38; P ϭ .7) and D356N (OR for NN/DD ϭ 1.53, 95% CI ϭ 0.90 to 2.59; P ϭ .2). There are presently no other published case-control studies on these two SHBG SNPs.
What would explain the apparent discrepancy? These SNPs show significant associations with circulating sex hormone lev- Supplementary Table A2 (available at http://jncicancerspectrum.oupjournals. org/jnci/content/vol96/issue12/. The case-control series is ongoing; hence, the sample size ranges from 1558 to 6265 subjects. els, known to be risk factors for breast cancer, but the same SNPs fail to show a significant direct association with breast cancer risk. A recent study has calculated that a doubling of circulating estradiol levels is associated with a 29% increase in breast cancer risk (3). If we assume that estradiol levels within a genotype class are log-normally distributed, then on the basis of the mean values of estradiol associated with the CYP19 3ЈUTR c-t genotypes, the tt genotype (mean estradiol level ϭ 17.1 pmol/L) would confer an odds ratio for breast cancer of 1.05 and the tc genotype (mean estradiol level ϭ 15.7 pmol/L) would confer an odds ratio of 1.02, relative to the cc genotype (mean 15.0 pmol/L). In practice, the true relationship between estradiol levels and breast cancer risk is likely to be stronger than these calculated values (we have measured levels at only one point in time, and true exposure will be the integral sum of levels over a lifetime). Thomas et al. (22) report an intra-class correlation of .56 between measurements of estradiol levels made in the same individual at different times in their prospective study, suggesting that approximately 50% of variance in estradiol levels is essentially random fluctuation. Consequently, we would predict odds ratios of 1.10 and 1.03 in women with the tt and tc genotypes, respectively. A study of approximately 34 000 cases and a similar number of matched controls would be required to detect a risk of this magnitude (50% power, significance level ϭ .0001)-more than an order of magnitude larger than the genetic association studies that have been published to date.
Our data help explain why the results obtained in breast cancer case-control studies have been largely inconclusive. The assumption on which they were based-that genetic variability in factors controlling the bioavailability of estrogens is likely to confer differential risk of developing breast cancer-remains correct. We have detected highly statistically significant associations between common genetic variants in both the CYP19 and SHBG genes and circulating sex hormone levels, but the small magnitude of these effects would only marginally increase the risk of developing breast cancer.
